Background: We examined the utility of quantification of α-synuclein (SNCA) in the cerebrospinal fluid (CSF) to differentiate patients with Alzheimer disease (AD), dementia with Lewy bodies (DLB), Parkinson disease (PD), and multiple system atrophy (MSA).
Methods: Thirty-seven patients were divided into 4 age-matched and sex-matched clinical groups: AD (n=9), DLB (n=6), PD (n=11), and MSA (n=11). Eleven subjects served as neurological disease controls. The total of 48 subjects included 27 men and 21 women, aged 66.5±11.4 years. We performed a solid-phase sandwich enzyme-linked immunosorbent assay, which enables the sensitive quantification of CSF SNCA.
Results: In comparison with controls, CSF SNCA levels in AD were significantly higher (P<0.05). CSF SNCA levels in PD (P<0.001), DLB (P<0.01), and MSA (P<0.05) were all significantly lower than those in AD. However, CSF SNCA levels did not differ significantly among the 3 synucleinopathies.
Conclusions: The results of the present study suggest that quantification of CSF SNCA helps in the differentiation of synucleinopathies (PD, DLB, and MSA) from AD. However, CSF SNCA levels did not differ significantly among the 3 synucleinopathies.
*Department of Internal Medicine, Neurology Division
†Research Advancement Unit, Sakura Medical Center, Toho University, Sakura, Japan
The authors declare no conflicts of interest.
Reprints: Ryuji Sakakibara, MD, PhD, Department of Internal Medicine, Sakura Medical Center, Neurology Division, Toho University, 564-1 Shimoshizu, Sakura 285-8741, Japan (e-mail: firstname.lastname@example.org).
Received September 21, 2010
Accepted September 17, 2011